Akoustis Technologies Stock Forecast, Price & News

Akoustis Technologies (NASDAQ:AKTS) Frequently Asked Questions

Is Akoustis Technologies a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Akoustis Technologies stock.
View analyst ratings for Akoustis Technologies or view top-rated stocks.

What stocks does MarketBeat like better than Akoustis Technologies?

Wall Street analysts have given Akoustis Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akoustis Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Akoustis Technologies' next earnings date?

Akoustis Technologies is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Akoustis Technologies.

How were Akoustis Technologies' earnings last quarter?

Akoustis Technologies, Inc. (NASDAQ:AKTS) released its earnings results on Sunday, August, 29th. The technology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.01. The technology company had revenue of $2.20 million for the quarter, compared to analyst estimates of $2.50 million. Akoustis Technologies had a negative trailing twelve-month return on equity of 42.85% and a negative net margin of 667.21%. The firm's quarterly revenue was up 501.1% compared to the same quarter last year.
View Akoustis Technologies' earnings history.

How has Akoustis Technologies' stock price been impacted by COVID-19?

Akoustis Technologies' stock was trading at $5.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKTS shares have increased by 95.3% and is now trading at $10.37.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AKTS?

5 brokers have issued 12 month target prices for Akoustis Technologies' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Akoustis Technologies' stock price to reach $17.40 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price.
View analysts' price targets for Akoustis Technologies or view top-rated stocks among Wall Street analysts.

Who are Akoustis Technologies' key executives?

Akoustis Technologies' management team includes the following people:

• Jeffrey B. Shealy, President, Chief Executive Officer & Director (LinkedIn Profile)
• Robert Dry, Vice President-Operations & Test
• Kenneth Boller, Chief Financial Officer & Controller (LinkedIn Profile)
• David M. Aichele, Executive Vice President-Business Development (LinkedIn Profile)
• Rohan Houlden, Chief Product Officer (LinkedIn Profile)

Who are some of Akoustis Technologies' key competitors?

Some companies that are related to Akoustis Technologies include Infinera (INFN), Avaya (AVYA), Telkom SA SOC (TLKGY), Plantronics (POLY), AudioCodes (AUDC), NETGEAR (NTGR), ADTRAN (ADTN), Clearfield (CLFD), DZS (DZSI), Exlites Holdings International (EXHI), Sunworks (SUNW), Communications Systems (JCS), Franklin Wireless (FKWL), Minim (MINM) and Altigen Communications (ATGN).
View all of AKTS's competitors.

What other stocks do shareholders of Akoustis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Square (SQ), Editas Medicine (EDIT), Marvell Technology (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

What is Akoustis Technologies' stock symbol?

Akoustis Technologies trades on the NASDAQ under the ticker symbol "AKTS."

Who are Akoustis Technologies' major shareholders?

Akoustis Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.49%), Vanguard Group Inc. (4.48%), Ashford Capital Management Inc. (3.84%), Handelsbanken Fonder AB (2.28%), Silverback Asset Management LLC (1.83%) and Geode Capital Management LLC (1.46%). Company insiders that own Akoustis Technologies stock include Arthur Geiss, David Aichele, Jeffrey B Shealy, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends for Akoustis Technologies.

Which major investors are selling Akoustis Technologies stock?

AKTS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Susquehanna International Group LLP, Goldman Sachs Group Inc., Advisor Group Holdings Inc., Cambridge Investment Research Advisors Inc., Bank of America Corp DE, Taylor Frigon Capital Management LLC, and Squarepoint Ops LLC. Company insiders that have sold Akoustis Technologies company stock in the last year include Arthur Geiss, David Aichele, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars, and Suzanne B Rudy.
View insider buying and selling activity for Akoustis Technologies or view top insider-selling stocks.

Which major investors are buying Akoustis Technologies stock?

AKTS stock was purchased by a variety of institutional investors in the last quarter, including Penserra Capital Management LLC, Connors Investor Services Inc., M&G Investment Management Ltd., Endurance Wealth Management Inc., Silverback Asset Management LLC, Vanguard Group Inc., BlackRock Inc., and State Street Corp.
View insider buying and selling activity for Akoustis Technologies or or view top insider-buying stocks.

How do I buy shares of Akoustis Technologies?

Shares of AKTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akoustis Technologies' stock price today?

One share of AKTS stock can currently be purchased for approximately $10.37.

How much money does Akoustis Technologies make?

Akoustis Technologies has a market capitalization of $532.83 million and generates $6.62 million in revenue each year. The technology company earns $-44,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Akoustis Technologies have?

Akoustis Technologies employs 99 workers across the globe.

What is Akoustis Technologies' official website?

The official website for Akoustis Technologies is www.akoustis.com.

Where are Akoustis Technologies' headquarters?

Akoustis Technologies is headquartered at 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078.

How can I contact Akoustis Technologies?

Akoustis Technologies' mailing address is 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078. The technology company can be reached via phone at (704) 997-5735 or via email at [email protected].